AdAlta (ASX:1AD)
ASX announcement history & article coverage
Transparent by design.
Announcments by AdAlta (ASX:1AD) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
EW-001 JDC milestone approvals
AdAlta advances EW-001 toward Australian Phase 1 trials with FDA briefing and manufacturing transfer approvals
China Representative Office opens
AdAlta receives approval to open Shanghai representative office and expand China cellular immunotherapy strategy
Date of AGM & Closing Date for Director Nominations
US FDA grants EW-001 pre-IND meeting
FDA accepts AdAlta request for pre-IND meeting on EW-001 CAR-T therapy
Oribiotech deal validates AdAlta manufacturing strategy
AdAlta says US$120 million Oribiotech deal validates its future CAR-T manufacturing platform
CAR-TCR Summit poster
Bilingual BIOSeedin Investor Presentation
BZDS1901 special access scheme launch in China
AdAlta partner approved to provide CAR-T therapy for advanced mesothelioma in China under special access scheme
Appendix 4G and Corporate Governance Statement
Annual Report to shareholders
AdAlta advances cellular immunotherapy pipeline, secures first asset, raises A$5.3M, reports FY2026 loss
Preliminary Final Report
Investor presentation
EW-001 IIT study overall survival update
AdAlta reports ongoing patient survival and promising response rates in EW-001 mesothelioma trial
2 year survival milestone for EW-001 patient
AdAlta's EW-001 CAR-T Therapy Shows Durable Complete Responses in Advanced Mesothelioma
Quarterly Appendix 4C and Activities Report
AdAlta secures EW-001 CAR-T rights, advances manufacturing and FDA engagement, raises A$2.5M, and boosts AI capabilities
ISCTANZ2026 presentation and poster